• ABOUT
  • THE GROUP
  • NEWS & MEDIA
  • EVENTS
  • CAREER
  • CONTACT US
  • 0

PD-L1 IHC 22C3 pharmDx

PD-L1 IHC 22C3 pharmDx
PD-L1 IHC 22C3 pharmDx Advancing Immunotherapy Options Cytotoxic T cells work to detect and eliminate infected cells and tumor cells from the body.
Read More
Add to Shortlist

Product Details

Our pharmDx Solution is a portfolio of all-in-one pharmDx kits that lead to optimal diagnostic results within companion diagnostics. Correct results the first time help select the right therapy for each patient - every time. pharmDx is all about personalized medicine pharmDx kits make a difference to the assessment of patient treatment. The validated kits have the right specificity and sensitivity. Correct results the first time lead to fewer reruns and will help select the right therapy for each patient - every time. We help improve patient care by delivering fast results with great confidence and reducing time from biopsy to diagnosis.

PD-L1 IHC 22C3 pharmDx Advancing Immunotherapy Options Cytotoxic T cells work to detect and eliminate infected cells and tumor cells from the body. To limit damage to surrounding tissue, normal cells differentiate themselves by expressing a protein signal called PD-L1 (programmed death ligand 1). This PD-L1 signal is a stop sign designed to avoid elimination of normal cells by cytotoxic T cells. T cells detect the PD-L1 signal through a receptor called PD-1 (programmed death receptor 1). Some tumors can also express the PD-L1 signal to mimic normal cells and escape elimination. Anti-PD-1 therapy works by blocking the PD-1/PD-L1 interaction. PD-L1 expression may be associated with patient benefit from anti-PD-1 therapy.
Read More